Lithium-induced cognitive dysfunction assessed over 1-year hospitalisation: A case report
This report is valuable because it is one of the few to track changes in cognitive function over time in a patient with SILENT using objective measures over 1 year of hospitalisation.
Authors
- Yoshiteru Takekita (ORCID: https://orcid.org/0000-0003-2435-4033)
- Masaki Kato (ORCID: https://orcid.org/0000-0001-6727-7272)
- Toshihiko Kinoshita (ORCID: https://orcid.org/0000-0001-9901-9753)
- Yuji Murase (ORCID: https://orcid.org/0009-0004-2639-5810)
Institutions
- Kansai Medical University (JP)
Publication Details
- Journal
- South African Journal of Psychiatry
- Published
- 2024-09-26
- DOI
- https://doi.org/10.4102/sajpsychiatry.v30i0.2314
- Citations
- 1
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.39
Funders
- Eli Lilly and Company
- Pfizer
- Takeda Pharmaceutical Company
- Japan Research Foundation for Clinical Pharmacology
- Japanese Society of Clinical Neuropsychopharmacology
- Japan Agency for Medical Research and Development
- Daiichi-Sankyo
- Ministry of Health, Labour and Welfare
- Eisai
- Meiji Seika Pharma
- Shionogi
- Otsuka Pharmaceutical
- SENSHIN Medical Research Foundation
- Mitsubishi Tanabe Pharma Corporation
- Ono Pharmaceutical
- H. Lundbeck A/S
- MSD K.K.
- Eli Lilly Japan
- Japan Society for the Promotion of Science